Physician profile
Saba Salahuddin
NPI 1821595042
$3,599.30
in general payments reported to CMS, 2019-2025
38 companies · $1,022 in 2025
The $1,022 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $68.07 · 2022: $525 · 2023: $732 · 2024: $1,252 · 2025: $1,022.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,006.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,005.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $593.06 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $466.14 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $276.45 | 2022-2025 | Evenity, Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $182.24 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $173.58 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $162.41 | 2022-2024 | Xifaxan, Trulance |
| Daiichi Sankyo INC. | $154.94 | 2022-2025 | Injectafer |
| Ucb, INC. | $153.40 | 2025 | Bimzelx |
| Otsuka America Pharmaceutical, INC. | $142.93 | 2023-2024 | Rexulti |
| Pfizer INC. | $128.38 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $126.63 | 2023-2024 | Gemtesa |
| Glaxosmithkline, LLC. | $117.88 | 2022-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Calliditas Therapeutics US INC. | $113.33 | 2024 | |
| Abbott Laboratories | $100.42 | 2024-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $54.54 | 2025 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saba Salahuddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.